For nearly 4 million Americans, low vision is an everyday reality. In fact, visual impairment is actually the leading cause of disability within the United States. Unfortunately, the number of those impacted is increasing annually at a startling rate, indicating the immediate need for a reliable, cost-effective and useful solution.
In support of their ongoing commitment to those challenged with low vision, Eyedaptic presented new data at Envision West on October 5, where. Dr. Rebecca Kammer, OD demonstrated life-enhancing features of the EYE01 first-generation prototype, designed to enable improved vision endpoints, to benefit those who struggle with low vision and specifically those with AMD (Age-Related Macular Degeneration).
Envision is an organization that promotes independence for those with low vision. Headquartered in Wichita, Kansas and founded in 1933, Envision is one of the largest employers of individuals with vision loss in the nation. Their mission is to provide inspiration and opportunity for people who are visually impaired through employment, outreach, rehabilitation, education and research. “We were gratified by the response to the presentation of additional data on patient usage of the EYE01 visual aid solution,” stated Dr. Kammer. “At last, the low vision community can experience a visual aid solution that allows individuals the opportunity to regain a quality life and independence lost due to their degenerating vision.”
The EYE01 prototype meets multiple visual needs including at distance, intermediate, and close up with the potential to essentially replace multiple devices. The most recent study explored the capabilities of EYE01 with AMD (Age-Related Macular Degeneration) patients in their home setting, performing simple tasks such as continuous text reading and independent tasks of daily living.
On October 13, at the American Academy of Ophthalmology at the Moscone Center, in San Francisco, CA, Eyedaptic’s Chief Medical Officer Mitul Mehta, MD will present their story along with clinical and user evaluation data in their presentation, “Performance of an Augmented Reality Device on Functional Activities”. The EYE01 efficacy data from the completed clinical trial reinforces improved reading acuity along with greater independence performing everyday activities.
The American Academy of Ophthalmology is comprised of a global community of 32,000 medical doctors, committed to setting the standards for ophthalmic education and advocating for patients and the public. Their mission is to innovate in order to ensure the delivery of the highest-quality eye care. “Low vison caused by retinal disorders is a huge unmet need that continues to plague our community,” stated Dr. Mehta. “We are very excited to share real-life usage and objective data supporting improved vision endpoints with our EYE01 visual aid solution.”